GoodRx Reports Decline in Revenue and Net Income for Q2 2026

GoodRx Holdings, Inc. reported a decline in financial performance for the second quarter of 2026, with total revenue of $200.4 million, down from $203.1 million in the same period last year. The company's net income also decreased to $8.5 million, compared to $12.8 million in the prior year, resulting in a net income margin of 4.3%, down from 6.3%. For the first half of 2026, revenue totaled $394.4 million, a decrease from $406.0 million in the first half of 2025, while net income fell to $9.7 million from $23.9 million.

The decline in revenue was primarily attributed to a significant drop in prescription transactions revenue, which decreased by 26% year-over-year to $106.4 million. This decline was driven by a reduction in Monthly Active Consumers, influenced by changes in the retail pharmacy landscape, including store closures and a decrease in claims volume from integrated savings programs. In contrast, subscription revenue increased by 39% to $28.5 million, reflecting growth in condition-specific subscription programs, while Pharma Direct revenue surged by 76% to $61.6 million, driven by expanded market penetration with pharmaceutical manufacturers.

GoodRx has made strategic moves to adapt to the evolving healthcare landscape, including the launch of new subscription offerings and a focus on expanding its Pharma Direct services. The company introduced GoodRx Companion, a subscription service providing access to low-cost medications and online care visits. Additionally, GoodRx is integrating its services with a new government-sponsored platform, TrumpRx, aimed at offering discounts on certain medications. These initiatives are part of a broader strategy to enhance consumer engagement and address the growing demand for pricing transparency in healthcare.

Operationally, GoodRx reported a decrease in Monthly Active Consumers, which fell to 5.0 million in June 2026 from 5.7 million a year earlier. The company also noted a reduction in its employee headcount, contributing to a decrease in product development and technology expenses. Despite these challenges, GoodRx's cash and cash equivalents increased to $296.1 million as of June 30, 2026, up from $261.8 million at the end of 2025, indicating a solid liquidity position.

Looking ahead, GoodRx anticipates continued pressure on its prescription transactions revenue and Monthly Active Consumers in the near term, as it shifts focus toward subscription and Pharma Direct offerings. The company remains committed to enhancing its platform and expanding its market presence, with expectations of long-term growth despite current challenges.